Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
Filippo Gustavo Dall’Olio, Wael Zrafi, Damien Vasseur, Camilo Garcia et autres
Baseline clinical characteristics of patients included in Flatiron HealthFoundation Medicine NSCLC clinico-genomic database (FH-FMI CGDB) study according to treatment received (ICB monotherapy vs combination with chemotherapy).
Filippo Gustavo Dall’Olio, Wael Zrafi, Damien Vasseur, Camilo Garcia et autres
Analysis restricted to patients with PD-L1 ≥50% and validation in the STING cohort.
Filippo Gustavo Dall’Olio, Wael Zrafi, Damien Vasseur, Camilo Garcia et autres
Baseline clinical characteristics of patients included in Flatiron HealthFoundation Medicine Clinico-Genomic Database (FH-FMI CGDB) by trichotomized ctDNA TF
Filippo Gustavo Dall’Olio, Wael Zrafi, Damien Vasseur, Camilo Garcia et autres
Baseline clinical characteristics of patients included in Flatiron HealthFoundation Medicine NSCLC clinico-genomic database (FH-FMI CGDB) study according PD-L1 known or unknown.
Filippo Gustavo Dall’Olio, Wael Zrafi, Damien Vasseur, Camilo Garcia et autres
Kaplan Meyer curves for rwOS for patients treated with immunotherapy single agent (A) or in combination (B). Multivariate models for immunotherapy single agent (C) and combination (D)
Filippo Gustavo Dall’Olio, Wael Zrafi, Damien Vasseur, Camilo Garcia et autres
Cohort diagram
Filippo Gustavo Dall’Olio, Wael Zrafi, Damien Vasseur, Camilo Garcia et autres
forest plot showing multivariable models for Progression Free Survival (PFS, left) and Overall Survival (OS, right) in patients with Tumor Fraction (TF) < 1% (A-B), 1-10% (C-D) and ≥ 10% (E-F) in the FH-FMI CGDB cohort.
Filippo Gustavo Dall’Olio, Wael Zrafi, Damien Vasseur, Camilo Garcia et autres
Baseline clinical characteristics of patients included in STING study for cutoff validation according to treatment received (ICB monotherapy vs combination with chemotherapy) and according to TF ≥ 5% vs TF < 5
Filippo Gustavo Dall’Olio, Wael Zrafi, Damien Vasseur, Camilo Garcia et autres
Imbalance according to treatment (A). Interaction between treatment and ctDNA tumor fraction (5% cutoff) for rwOS (B) and rwPFS (C).
Filippo Gustavo Dall’Olio, Wael Zrafi, Damien Vasseur, Camilo Garcia et autres
Sensitivity analysis in patients with available PD-L1 results. (A) Residual covariate imbalance after IPTW. Similar hazard ratios were observed for rwPFS (HR 0.55, 95% CI 0.32–0.96; B) and rwOS (HR 0.49, 95% CI 0.28–0.88; C).
Filippo Gustavo Dall’Olio, Wael Zrafi, Damien Vasseur, Camilo Garcia et autres
Abstract Purpose: Immune checkpoint blockers (ICB) have transformed advanced non–small cell lung cancer (aNSCLC) treatment, but identifying patients who benefit from adding chemotherapy remains challenging, especially in PD-L1 ≥ 50%. PD-L1 is an imperfect biomarker, highlighting the need for better selection tools. …
Filippo Gustavo Dall’Olio, Wael Zrafi, Damien Vasseur, Camilo Garcia et autres
Oncoplot showing main molecular alteration according to tumor fraction (TF), metabolic tumor volume (tMTV), liver and brain mutations, age and gender
BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.
L'essentiel de l'actu tech du Burkina & d'Afrique, chaque semaine dans votre boîte mail.
Gratuit · sans spam · désinscription en un clic